Phase III
In a Phase III trial, Cosentyx showed a significant and clinically meaningful reduction in disease activity for patients versus placebo.
TLC announced the initiation of a Phase III clinical trial (“EXCELLENCE”) to evaluate the efficacy and safety of single as well as repeated doses of TLC599 in patients with osteoarthritis (OA) of the knee.
TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo
Phase III trial validates the benefit of veliparib for patients without a BRCA mutation
Hutchison China MediTech Limited presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic at the 2019 European Society for Medical Oncology Congress.
Merck’s vaunted checkpoint inhibitor Keytruda combined with chemotherapy proved to be more efficacious than chemotherapy alone as neoadjuvant therapy in pre- and post-surgery triple-negative breast cancer patients.
Nicholas Kartsonis, head of clinical research in infectious diseases and vaccines at Merck Research Laboratories, noted that additional treatment options are needed for critically ill patients with respiratory infections.
Treatment with Erleada plus androgen deprivation therapy resulted in a 25% reduction in the risk of death compared to placebo in prostate cancer patients.
Pfizer announced positive top-line results from the first trial in May.
Hutchison China MediTech Limited will showcase data from its proprietary clinical programs at the 2019 European Society for Medical Oncology Congress on September 27 to October 1, 2019 in Barcelona, Spain.
PRESS RELEASES